Abstract
Helicobacter pylori infection is a major cause of many diseases of the gastrointestinal tract, including gastritis, non-ulcer dyspepsia, peptic ulcer disease, and gastric cancers. It is estimated that more than half of the human race is affected by this organism. Although effective treatments are available which will eliminate the organism in about 90percent of cases in developed countries, the pandemic occurrence of Helicobacter pylori infection coupled with its ability to develop resistance to our current arsenal of antimicrobial regimens and subsequently reinfect patients makes the pathogenic potential of this microorganism a major global health concern. Provided is a review of the current and evolving therapeutic regimens used in the eradication of Helicobacter pylori, the difficulties associated with in vitro drug screening, as well as potentially new therapeutic targets. In addition, the discovery, the unique physiology, biochemistry, and pathogenicity of this remarkable microorganism is examined.
Keywords: Helicobacter pylori, Gastritis, Non-ulcer dyspepsia, Peptic ulcer disease, Gastric cancers, Compylobacter jejuni, Adhesion factor, Urease, Inflammation, VacA
Current Pharmaceutical Design
Title: Helicobacter pylori Current Chemotherapy and New Targets for Drug Design
Volume: 7 Issue: 5
Author(s): John S. Williamson
Affiliation:
Keywords: Helicobacter pylori, Gastritis, Non-ulcer dyspepsia, Peptic ulcer disease, Gastric cancers, Compylobacter jejuni, Adhesion factor, Urease, Inflammation, VacA
Abstract: Helicobacter pylori infection is a major cause of many diseases of the gastrointestinal tract, including gastritis, non-ulcer dyspepsia, peptic ulcer disease, and gastric cancers. It is estimated that more than half of the human race is affected by this organism. Although effective treatments are available which will eliminate the organism in about 90percent of cases in developed countries, the pandemic occurrence of Helicobacter pylori infection coupled with its ability to develop resistance to our current arsenal of antimicrobial regimens and subsequently reinfect patients makes the pathogenic potential of this microorganism a major global health concern. Provided is a review of the current and evolving therapeutic regimens used in the eradication of Helicobacter pylori, the difficulties associated with in vitro drug screening, as well as potentially new therapeutic targets. In addition, the discovery, the unique physiology, biochemistry, and pathogenicity of this remarkable microorganism is examined.
Export Options
About this article
Cite this article as:
Williamson S. John, Helicobacter pylori Current Chemotherapy and New Targets for Drug Design, Current Pharmaceutical Design 2001; 7 (5) . https://dx.doi.org/10.2174/1381612013397979
DOI https://dx.doi.org/10.2174/1381612013397979 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Rational Targeting of the Urokinase Receptor (uPAR): Development of Antagonists and Non-Invasive Imaging Probes
Current Drug Targets Pharmacological Control of Autophagy: Therapeutic Perspectives in Inflammatory Bowel Disease and Colorectal Cancer
Current Pharmaceutical Design Screening and Development of Transglutaminase-2 Inhibitors and their Derivative as Anti-lung Cancer Agent by in silico and in vitro Approaches
Current Computer-Aided Drug Design Plant-Derived Biomolecules and Drug Delivery Systems in the Treatment of Liver and Kidney Diseases
Current Pharmaceutical Design IAPs as a Target for Anticancer Therapy
Current Cancer Drug Targets Cisplatin Properties in a Nanobiotechnological Approach to Cancer: A Mini-Review
Current Cancer Drug Targets Editorial [Hot Topic: Anti-Inflammatory Therapy (Guest Editor: Dr. Subhash P. Khanapure)]
Current Topics in Medicinal Chemistry The Role of STAT3 Signaling in Mediating Tumor Resistance to Cancer Therapy
Current Drug Targets Comparative Proteomic Profiling of Extracellular Proteins between Normal and Gastric Cancer Cells
Current Cancer Drug Targets Flavonoid-Based Cancer Therapy: An Updated Review
Anti-Cancer Agents in Medicinal Chemistry Clinical Evaluation of Anti-Obesity Drugs
Current Drug Targets Chondroitin Sulphate for the Treatment of Osteoarthritis
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Fat Digestion and its Role in Appetite Regulation and Energy Balance -The Importance of Enterostatin and Tetrahydrolipstatin
Current Medicinal Chemistry - Central Nervous System Agents Hepato and Cardiotoxicity of Chemotherapeutic Treatment Evaluated by Means of Small Animal Imaging
Anti-Cancer Agents in Medicinal Chemistry More Good News About Polymeric Plant- and Algae-Derived Biomaterials in Drug Delivery Systems
Current Drug Targets Mechanisms of Drug Resistance in Cancer Chemotherapy: Coordinated Role and Regulation of Efflux Transporters and Metabolizing Enzymes
Current Pharmaceutical Design Anticarcinogenic Actions of Tributyrin, A Butyric Acid Prodrug
Current Drug Targets Overexpression of Nemo-like Kinase Promotes the Proliferation and Invasion of Lung Cancer Cells and Indicates Poor Prognosis
Current Cancer Drug Targets Transdermal Oxandrolone: Ex Vivo Percutaneous Absorption Study
Current Drug Delivery MiR-143HG Gene Polymorphisms as Risk Factors for Gastric Cancer in Chinese Han Population
Current Molecular Medicine